Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)

Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed

Presentation on September 30, 2023

OSLO, Norway--(BUSINESS WIRE)--Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the presentation of initial safety data from the ongoing Phase 1 clinical trial evaluating the recommended dose, safety and tolerability of Radspherin^® in patients with recurrent ovarian cancer at the 24^th Congress of the European Society of Gynaecological Oncology (ESGO) being held at the Istanbul Congress Center in Istanbul, Türkiye from September 28 – October 1, 2023. The presentation, titled “First Experience With Intra-Abdominal ²²⁴Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)” will be presented on September 30, 2023 from 9:24 a.m. to 9:32 a.m. local time (5:24 a.m. ET).

"Oncoinvent is proud to present safety data from our lead candidate, Radspherin^® at a major congress of the global gynecological cancer community. We believe this is an important first step as we advance the development of Radspherin^® as a new treatment for patients with advanced ovarian cancer,” says CEO Anders Månsson.

Details of the presentation are as follows:

Session: MO3 Mini Oral Session - Ovarian Cancer
Presentation Title: First Experience With Intra-Abdominal ²²⁴Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)
Presentation Board Number: 850
Presenting Author: Els Van Nieuwenhuysen, MD
Presentation Date and Time: September 30^th, 2023, from 9:24 a.m. to 9:32 a.m. local time (5:24 a.m. ET)

The ongoing Phase 1 study is designed to evaluate the recommended dose, safety and tolerability of Radspherin^® injected intraperitoneally following secondary cytoreductive surgery. The safety interim analysis after completion of the dose-limiting toxicity (DLT) period demonstrated that Radspherin^® was well tolerated. The highest dose of 7 MBq was recommended following the completion of dose escalation of 1-2-4-7 MBq, as no DLT was observed.

About Oncoinvent

Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent’s lead candidate, Radspherin^®, is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. Radspherin^® is in two ongoing clinical studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.